from time to time, i have heard that we are at the current price per share because of the high marks ponatnib has received. and that the price reflects a pre-determined approval from the fda. If thats the case, does anyone think that the price should go higher upon an actual approval, as i think it should? Or at this point, does a separate catalyst need to take place, in order to breath in a new life of highs, from its current price?